Corporate Sustainability and Social Impact Report

The report highlights the company's 2024 progress in patient-centric innovation, including FDA approval for a treatment for adults with Biliary Tract Cancer. It also describes strengthened ESG governance through formal Audit Committee oversight of external ESG disclosures. Environmental progress included improved collection of verifiable data and expanded renewable-energy activities, while the report disclosed a workforce of 2,803 employees.